Nakajima I, Ozaki M, Jinnai H, Shilayama Y, Hirohata T, Okuno K, Yasutomi M
First Department of Surgery, Kinki University School of Medicine, Osakasayama, Japan.
Cancer Biother. 1993 Winter;8(4):319-26. doi: 10.1089/cbr.1993.8.319.
The antitumor activity of Interleukin-1 (IL-1), was assessed against the murine adenocarcinoma colon 26 tumor model in combination with Interleukin-2 (IL-2). Colon 26 tumor cells were inoculated on the back of syngeneic BALB/c mice. Fourteen days after inoculation, when the tumor nodule reached approximately 10 mm in diameter, tumor nodules were resected and Hank's solution, IL-2, IL-1, or IL-2 plus IL-1 were injected directly into the mouse spleen. One week after treatment, potent natural killer (NK) and enhanced lymphokine activated killer (LAK) cell activities were seen in the splenocytes treated by the combination of IL-2 plus IL-1. Furthermore the combination treatment by IL-2 plus IL-1 resulted in a significantly prolonged survival. Phenotypic analysis showed an increased number of percent positive cells expressing asialo GM 1 and IL-2 receptor after treatment with IL-2 plus IL-1. A possible role of IL-1 in augmentation of IL-2 dependent antitumor activity in vivo is discussed.
研究了白细胞介素-1（IL-1）与白细胞介素-2（IL-2）联合应用对小鼠结肠腺癌26肿瘤模型的抗肿瘤活性。将结肠26肿瘤细胞接种于同基因BALB/c小鼠的背部。接种后14天，当肿瘤结节直径达到约10毫米时，切除肿瘤结节，并将汉克氏溶液、IL-2、IL-1或IL-2加IL-1直接注射到小鼠脾脏中。治疗一周后，在经IL-2加IL-1联合处理的脾细胞中观察到强大的自然杀伤（NK）细胞活性和增强的淋巴因子激活杀伤（LAK）细胞活性。此外，IL-2加IL-1的联合治疗显著延长了生存期。表型分析显示，用IL-2加IL-1处理后，表达去唾液酸GM1和IL-2受体的阳性细胞百分比增加。本文讨论了IL-1在体内增强IL-2依赖性抗肿瘤活性中的可能作用。
